Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial

To explore the activity and safety of two schedules of ixabepilone, as first line chemotherapy, in patients with metastatic breast cancer previously treated with adjuvant chemotherapy, a randomized non-comparative phase II study was conducted. From November 2008 until December 2010, 64 patients were...

Descripción completa

Detalles Bibliográficos
Autores principales: Fountzilas, George, Kotoula, Vassiliki, Pectasides, Dimitrios, Kouvatseas, George, Timotheadou, Eleni, Bobos, Mattheos, Mavropoulou, Xanthipi, Papadimitriou, Christos, Vrettou, Eleni, Raptou, Georgia, Koutras, Angelos, Razis, Evangelia, Bafaloukos, Dimitrios, Samantas, Epaminontas, Pentheroudakis, George, Skarlos, Dimosthenis V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720651/
https://www.ncbi.nlm.nih.gov/pubmed/23935969
http://dx.doi.org/10.1371/journal.pone.0069256

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720651/
https://www.ncbi.nlm.nih.gov/pubmed/23935969
http://dx.doi.org/10.1371/journal.pone.0069256

Ejemplares similares